Wednesday, January 15, 2025

GenSight Biologics Publishes 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ Gene Therapy

Five years after the one-time injection, patients with Leber hereditary optic neuropathy due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and a favorable safety profile. 

Wednesday, January 15, 2025

City Therapeutics Enters Into Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for GA

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Wednesday, January 15, 2025

Inflammasome Therapeutics Reports Topline 3-month Data from Clinical Trial of Dual Inflammasome Inhibitor, K8, in GA

In a US clinical trial of five patients with bilateral geographic atrophy, sustained-release intravitreous implants of K8 were well tolerated, with no drug-related ocular or systemic serious adverse events.

Tuesday, January 14, 2025

Data Show Implantable Telescope Improves Vision in Advanced AMD

Samsara Vision reported intermediate-term visual and safety outcomes of a study of the SING IMT in patients 6 months post-surgery.

Tuesday, January 14, 2025

Interim Results Reported From 4D-150 SPECTRA Clinical Trial in DME

The 3E10 vg/eye dose demonstrated notable efficacy, achieving sustained visual acuity gains.

Monday, January 13, 2025

Bausch + Lomb Acquires Whitecap Biosciences

With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Bioscience's strengthens B + L’s expanding clinical-stage pipeline. 

Tuesday, January 7, 2025

Sozinibercept Shows Efficacy as DME Treatment

Recently published results of a phase 1 study support its potential in combination with aflibercept.

Tuesday, January 7, 2025

Canyon Labs Acquires iuvo BioScience’s Lab Division

The deal allows each company to focus on strengths.

Monday, January 6, 2025

Regeneron Acquires UK Biotech Firm Oxular

Monday, January 6, 2025

Cencora Finalizes RCA Acquisition

Monday, January 6, 2025

Smart Glasses for Vision Loss Debut at CES 2025

SolidddVision’s vision correction technology can improve sight for patients with macular degeneration and other conditions.

Monday, January 6, 2025

OCS-05 Shows Efficacy in Treating Acute Optic Neuritis

ACUITY trial reveals potential to improve retinal structure and vision.

Monday, January 6, 2025

EssilorLuxottica to Acquire Espansione Group

The deal to acquire the Italian company expands Essilor’s medical technology portfolio.

Monday, January 6, 2025

Galimedix Begins Trial for Dry AMD Eye Drops

The phase 2 study will examine GAL-101’s potential to slow the growth of geographic atrophy lesions.